Meeting
2018 Genitourinary Cancers Symposium
Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer.
Authors
Michal Sarfaty
Davidoff Cancer Center, Petach Tikva, Israel
Michal Sarfaty , Peter Hall , Kelvin K. Chan , Kiran Virik , Moshe Leshno , Noa Gordon , Assaf Moore , Victoria Neiman , Eli Rosenbaum , Daniel A. Goldstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 472)
DOI
10.1200/JCO.2018.36.6_suppl.472
Abstract #
472
Poster Bd #
J1
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness-analysis of different treatment modalities in bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NIMBC).
First Author: Constantin Rieger
Poster
2023 ASCO Quality Care Symposium
Comparative cost-effectiveness analysis of oral agents for advanced EGFR mutated and ALK-positive non-small cell lung cancer.
First Author: Dali Edwards
Poster
2023 ASCO Annual Meeting
Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.
First Author: James Dickerson
Poster
2023 ASCO Gastrointestinal Cancers Symposium
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment.
First Author: Timothy Jay Price